168682-53-9
168682-53-9 结构式
基本信息
EZATIOSTAT游离的
GSTP1-1抑制剂(EZATIOSTAT)
Ezatiostat
Terrapin 199
Ezatiostat, >96%
Ezatiostat, >=98%
TER199(free base)
Ezatiostat (TER199)
Ezatiostat TFA (free base)
TER 199
TLK-199
TELINTRA
(2R)-L-gamma-Glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenylglycine 1,3-diethyl ester
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-13634A | EZATIOSTAT游离的 Ezatiostat | 168682-53-9 | 5mg | 744元 |
| 2024/04/30 | S9698 | EZATIOSTAT游离的 Ezatiostat | 168682-53-9 | 5mg | 795.31元 |
| 2024/04/30 | HY-13634A | EZATIOSTAT游离的 Ezatiostat | 168682-53-9 | 10mM * 1mLin DMSO | 867元 |
常见问题列表
| Target | Value |
|
GSTP1-1
() | |
|
JNK1
() | |
|
ERK1/ERK2
() |
Ezatiostat causes dissociation of the enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN) complex, leading to JNK activation by phosphorylation. The therapeutic action of ezatiostat appears to include both proliferation of normal myeloid progenitors as well as apoptosis of the malignant clone.
Selection of a resistant clone of an HL60 tumor cell line through chronic exposure to Ezatiostat (TLK199) results in cells with elevated activities of c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2, and allowes the cells to proliferate under stress conditions that induced high levels of apoptosis in the wild type cells.
Administration of Ezatiostat (TLK199), stimulates both lymphocyte production and bone marrow progenitor (colony-forming unit-granulocyte macrophage) proliferation, but only in glutathione S-transferase P1-1 (GSTP1 +/+ ) and not in GSTP1 -/- animals.